US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma: Dublin Friday, August 8, 2025, 11:00 Hrs [IST] Jazz Pharmaceuticals plc, ...

A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...

Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 4.8% in the afternoon session after the company ...

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

Modeyso is the first drug to treat patients with diffuse midline glioma with an H3 K27M mutation, an ultra-rare and aggressive brain tumor.

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...

The FDA granted accelerated approval to dordaviprone for the treatment of patients aged 1 year and older with recurrent diffuse midline glioma who harbor the H3 K27M mutation with progressive disease ...

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor that affects an estimated 2,000 people in the U.S. each year, many of whom are ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Ireland-headquartered Jazz Pharmaceuticals’ ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 ...